Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil

Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil

Abstract: Background: Psoriasis, a chronic, inflammatory skin disease, requires long-term therapy. Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin 23 by binding to its p19 subunit. Objective: The authors assessed the efficacy and safety of r...

Full description

Saved in:
Bibliographic Details
Main Authors: Tania F. Cestari, Cacilda da Silva Souza, Luna Azulay-Abulafia, Ricardo Romiti, André V.E. Carvalho, Caio César Silva de Castro, Sílvio Alencar Marques, João Roberto Antonio, Lincoln Fabrício, Ahmed M. Soliman, Tianshuang Wu, Ranjeeta Sinvhal, Vassilis Stakias, Alexandra P. Song, Jasmina Kalabic, Naomi Martin, Luiza Keiko Matsuka Oyafuso
Format: Article
Language:English
Published: Sociedade Brasileira de Dermatologia 2025-04-01
Series:Anais Brasileiros de Dermatologia
Subjects:
Methotrexate
Psoriasis
Risankizumab
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962025000200308&lng=en&tlng=en
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0365-05962025000200308&lng=en&tlng=en

Similar Items